AChE/GSK-3β-IN-1 is used for Alzheimer's disease research; it acts as a potent dual inhibitor of acetylcholinesterase (AChE) and glycogen synthase kinase-3β (GSK-3β), exhibits high selectivity against the CMGC kinase family, occupies the ATP-binding site of DYRK1A, and reduces oxidative stress by inhibiting ROS expression.